FDA to Collect $1.2 Billion in User Fees

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 8
Volume 11
Issue 8

WASHINGTON-President Bush has signed legislation that reauthorizes the Prescription Drug User Fee Act (PDUFA), first enacted in 1992 to speed up the FDA’s processing of new drug applications. PDUFA III is the second 5-year

WASHINGTON—President Bush has signed legislation that reauthorizes thePrescription Drug User Fee Act (PDUFA), first enacted in 1992 to speed up theFDA’s processing of new drug applications. PDUFA III is the second 5-yearextension. It authorizes collection of $1.2 billion in user fees in the next 5years from companies submitting NDAs.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content